These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 25584719

  • 1. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.
    Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu X, Sun H, Shan Z, Wang E, Luo Y, Yang X, Zhao J, Du J, El-Naggar AK, Teng W, Xing M.
    J Clin Endocrinol Metab; 2015 Apr; 100(4):E632-7. PubMed ID: 25584719
    [Abstract] [Full Text] [Related]

  • 2. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
    Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, Xing M.
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
    [Abstract] [Full Text] [Related]

  • 3. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE, Hwang TS, Choi YL, Han HS, Kim WS, Jang MH, Kim SK, Yang JH.
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [Abstract] [Full Text] [Related]

  • 4. Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
    Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK, Xing M.
    Endocr Relat Cancer; 2013 Aug; 20(4):603-10. PubMed ID: 23766237
    [Abstract] [Full Text] [Related]

  • 5. [BRAF V600E Mutation and TERT Promoter Mutation in Papillary Thyroid Carcinomas and Their Association with Clinicopathological Characteristics].
    Yang T, Chen C, Pan NF, Sun LY, Jiang XL, Li JN, Tang Y, Jiang Y.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
    [Abstract] [Full Text] [Related]

  • 6. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B, Godbert Y, Perot G, Al Ghuzlan A, Bardet S, Belleannée G, Crinière L, Do Cao C, Fouilloux G, Guyetant S, Kelly A, Leboulleux S, Buffet C, Leteurtre E, Michels JJ, Tissier F, Toubert ME, Wassef M, Pinard C, Hostein I, Soubeyran I.
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [Abstract] [Full Text] [Related]

  • 7. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M, Yan C, Xiao J, Wang T, Ling R.
    Diagn Pathol; 2019 Jul 12; 14(1):74. PubMed ID: 31300059
    [Abstract] [Full Text] [Related]

  • 8. Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis.
    Moon S, Song YS, Kim YA, Lim JA, Cho SW, Moon JH, Hahn S, Park DJ, Park YJ.
    Thyroid; 2017 May 12; 27(5):651-660. PubMed ID: 28181854
    [Abstract] [Full Text] [Related]

  • 9. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS, Kim Y, Jeon S, Kim SH, Kim TJ, Lee S, Kim MH, Lim DJ, Lee YS, Jung CK.
    Diagn Pathol; 2016 Feb 09; 11():21. PubMed ID: 26857243
    [Abstract] [Full Text] [Related]

  • 10. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
    Qasem E, Murugan AK, Al-Hindi H, Xing M, Almohanna M, Alswailem M, Alzahrani AS.
    Endocr Relat Cancer; 2015 Dec 09; 22(6):901-8. PubMed ID: 26354077
    [Abstract] [Full Text] [Related]

  • 11. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C, Xu D.
    Oncogene; 2014 Oct 16; 33(42):4978-84. PubMed ID: 24141777
    [Abstract] [Full Text] [Related]

  • 12. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, Tuttle RM, Sherman E, Gill AJ, Ghossein R.
    Thyroid; 2020 Oct 16; 30(10):1505-1517. PubMed ID: 32284020
    [Abstract] [Full Text] [Related]

  • 13. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S, Ozturk Sari S, Yegen G, Sormaz IC, Yilmaz I, Poyrazoglu S, Sanlı Y, Giles Senyurek Y, Kapran Y, Mete O.
    Endocr Pathol; 2016 Jun 16; 27(2):153-61. PubMed ID: 26951110
    [Abstract] [Full Text] [Related]

  • 14. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
    Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A, Sancisi V.
    Eur J Endocrinol; 2015 Apr 16; 172(4):403-13. PubMed ID: 25583906
    [Abstract] [Full Text] [Related]

  • 15. TERT promoter mutations in thyroid cancer.
    Liu R, Xing M.
    Endocr Relat Cancer; 2016 Mar 16; 23(3):R143-55. PubMed ID: 26733501
    [Abstract] [Full Text] [Related]

  • 16. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer.
    Trybek T, Walczyk A, Gąsior-Perczak D, Pałyga I, Mikina E, Kowalik A, Hińcza K, Kopczyński J, Chrapek M, Góźdź S, Kowalska A.
    Endocrinology; 2019 Oct 01; 160(10):2328-2338. PubMed ID: 31305897
    [Abstract] [Full Text] [Related]

  • 17. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation.
    Chakraborty D, Shakya S, Ballal S, Agarwal S, Bal C.
    J Pediatr Endocrinol Metab; 2020 Nov 26; 33(11):1465-1474. PubMed ID: 33027050
    [Abstract] [Full Text] [Related]

  • 18. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
    Jin L, Chen E, Dong S, Cai Y, Zhang X, Zhou Y, Zeng R, Yang F, Pan C, Liu Y, Wu W, Xing M, Zhang X, Wang O.
    Oncotarget; 2016 Apr 05; 7(14):18346-55. PubMed ID: 26943032
    [Abstract] [Full Text] [Related]

  • 19. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
    Teng L, Deng W, Lu J, Zhang J, Ren X, Duan H, Chuai S, Duan F, Gao W, Lu T, Wu H, Liang Z.
    Oncotarget; 2017 Mar 28; 8(13):22023-22033. PubMed ID: 28423545
    [Abstract] [Full Text] [Related]

  • 20. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
    Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA.
    J Clin Endocrinol Metab; 2013 Sep 28; 98(9):E1562-6. PubMed ID: 23833040
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.